Tekmira Pharmaceuticals Corporation Presents Positive Interim Results on Phase 1/2 Clinical Programs

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its clinical programs were presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy, which is taking place in in Washington, DC, May 21 to 24.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC